描述 |
Droloxifene,Tamoxifen 衍生物,是一种具有口服活性和选择性的雌激素受体 (estrogen receptor) 调节剂。Droloxifene 具有抗雌激素和抗植入作用。Droloxifene 诱导 MCF-7 细胞 p53 表达及凋亡。Droloxifene 预防去卵巢大鼠骨丢失。
|
相关类别 |
|
体外研究 |
Droloxifene(10nm;16-18h)诱导MCF-7细胞凋亡[1]。细胞活力测定[2]细胞株:MCF-7细胞浓度:10nm培养时间:16-18h结果:诱导细胞凋亡
|
体内研究 |
屈洛昔芬(5-20 mg/kg;p.o.;每日4周)以10 mg/kg的剂量增加DFM的骨密度,并完全防止20 mg/kg/天的剂量降低去卵巢(OVX)引起的DFM的骨密度和骨密度[3]。动物模型:5月龄假手术大鼠[3]剂量:5、10、20 mg/kg口服;每日4周结果:10 mg/kg时DFM的骨密度显著增加;20 mg/kg/d时完全阻止OVX所致DFM的骨密度和骨密度下降。
|
参考文献 |
[1]. Herrington DM, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthypostmenopausal women. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1606-12. [2]. Grasser WA, et al. Common mechanism for the estrogen agonist and antagonist activities of droloxifene. J Cell Biochem. 1997 May;65(2):159-71. [3]. Ke HZ, et al. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. ndocrinology. 1995 Jun;136(6):2435-41. [4]. Huang Y, et al. Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Acta Pharmacol Sin. 2005 Oct;26(10):1243-7.
|